脉络丛肿瘤 DNA 甲基化分析的临床实用性

IF 3.7 Q1 CLINICAL NEUROLOGY Neuro-oncology advances Pub Date : 2024-06-12 DOI:10.1093/noajnl/vdae097
K. Yeo, Cassie B Macrae, Bradley Gampel, Jared T Ahrendsen, H. Lidov, Karen D Wright, Susan Chi, Katie Fehnel, Lissa Baird, Jessica Clymer, Kenneth J Aldape, S. Alexandrescu
{"title":"脉络丛肿瘤 DNA 甲基化分析的临床实用性","authors":"K. Yeo, Cassie B Macrae, Bradley Gampel, Jared T Ahrendsen, H. Lidov, Karen D Wright, Susan Chi, Katie Fehnel, Lissa Baird, Jessica Clymer, Kenneth J Aldape, S. Alexandrescu","doi":"10.1093/noajnl/vdae097","DOIUrl":null,"url":null,"abstract":"\n \n \n Choroid plexus tumors (CPTs) are rare, potentially aggressive CNS tumors with defined histologic criteria for grading. In recent years, several patients within our practice have demonstrated discordance between the histologic diagnosis and clinical behavior. DNA methylation profiling has emerged as a potential diagnostic adjunct for aiding the clinical approach.\n \n \n \n We reviewed the clinical and pathologic data of all CPTs diagnosed at Boston Children’s Hospital from 1995-2023. All cases with available material (38/48) underwent DNA methylation profiling at NIH/NCI, and the classifier results were correlated with the WHO histologic grade and patient outcomes. Survival information was analyzed using Kaplan Meier curves.\n \n \n \n There was good correlation (11/12, 92%) between methylation class and WHO histologic grade for choroid plexus carcinomas (CPC); one histologic CPC grouped with choroid plexus papilloma (CPP) group pediatric (P). Five CPPs grouped with methylation class CPC (5/17, 29%). In the group of atypical CPPs (n=9), there were two that grouped with methylation class CPC. Survival analysis showed utility of methylation classes in the prediction of biologic behavior.\n \n \n \n Results indicated that methylation profiling may serve as a valuable tool in the clinical decision-making process for patients with CPTs, providing additional prognostic information compared to WHO histologic grade alone. The value of methylation array analysis is particularly important given the lack of consensus on treatment regimens for CPTs.\n","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Utility of DNA Methylation Profiling for Choroid Plexus Tumors\",\"authors\":\"K. Yeo, Cassie B Macrae, Bradley Gampel, Jared T Ahrendsen, H. Lidov, Karen D Wright, Susan Chi, Katie Fehnel, Lissa Baird, Jessica Clymer, Kenneth J Aldape, S. Alexandrescu\",\"doi\":\"10.1093/noajnl/vdae097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n Choroid plexus tumors (CPTs) are rare, potentially aggressive CNS tumors with defined histologic criteria for grading. In recent years, several patients within our practice have demonstrated discordance between the histologic diagnosis and clinical behavior. DNA methylation profiling has emerged as a potential diagnostic adjunct for aiding the clinical approach.\\n \\n \\n \\n We reviewed the clinical and pathologic data of all CPTs diagnosed at Boston Children’s Hospital from 1995-2023. All cases with available material (38/48) underwent DNA methylation profiling at NIH/NCI, and the classifier results were correlated with the WHO histologic grade and patient outcomes. Survival information was analyzed using Kaplan Meier curves.\\n \\n \\n \\n There was good correlation (11/12, 92%) between methylation class and WHO histologic grade for choroid plexus carcinomas (CPC); one histologic CPC grouped with choroid plexus papilloma (CPP) group pediatric (P). Five CPPs grouped with methylation class CPC (5/17, 29%). In the group of atypical CPPs (n=9), there were two that grouped with methylation class CPC. Survival analysis showed utility of methylation classes in the prediction of biologic behavior.\\n \\n \\n \\n Results indicated that methylation profiling may serve as a valuable tool in the clinical decision-making process for patients with CPTs, providing additional prognostic information compared to WHO histologic grade alone. The value of methylation array analysis is particularly important given the lack of consensus on treatment regimens for CPTs.\\n\",\"PeriodicalId\":94157,\"journal\":{\"name\":\"Neuro-oncology advances\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology advances\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.1093/noajnl/vdae097\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

脉络丛肿瘤(CPT)是一种罕见的、具有潜在侵袭性的中枢神经系统肿瘤,组织学上有明确的分级标准。近年来,在我们的临床实践中,有几例患者的组织学诊断与临床表现不一致。DNA 甲基化分析已成为辅助临床诊断的潜在辅助手段。 我们回顾了 1995-2023 年波士顿儿童医院诊断的所有 CPT 的临床和病理数据。所有有可用材料的病例(38/48)都在美国国立卫生研究院/国家癌症研究所进行了DNA甲基化分析,分类结果与WHO组织学分级和患者预后相关。采用卡普兰-梅耶曲线分析了生存信息。 脉络丛癌(CPC)的甲基化等级与WHO组织学分级之间存在良好的相关性(11/12,92%);1例组织学CPC与脉络丛乳头状瘤(CPP)组儿科(P)分组。5例CPP属于甲基化类CPC(5/17,29%)。在非典型 CPP 组(9 例)中,有 2 例属于甲基化类别 CPC。生存分析表明,甲基化类别在预测生物学行为方面很有用。 结果表明,甲基化分析可作为 CPT 患者临床决策过程中的一个有价值的工具,提供比单纯 WHO 组织学分级更多的预后信息。鉴于对 CPT 的治疗方案缺乏共识,甲基化阵列分析的价值尤为重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical Utility of DNA Methylation Profiling for Choroid Plexus Tumors
Choroid plexus tumors (CPTs) are rare, potentially aggressive CNS tumors with defined histologic criteria for grading. In recent years, several patients within our practice have demonstrated discordance between the histologic diagnosis and clinical behavior. DNA methylation profiling has emerged as a potential diagnostic adjunct for aiding the clinical approach. We reviewed the clinical and pathologic data of all CPTs diagnosed at Boston Children’s Hospital from 1995-2023. All cases with available material (38/48) underwent DNA methylation profiling at NIH/NCI, and the classifier results were correlated with the WHO histologic grade and patient outcomes. Survival information was analyzed using Kaplan Meier curves. There was good correlation (11/12, 92%) between methylation class and WHO histologic grade for choroid plexus carcinomas (CPC); one histologic CPC grouped with choroid plexus papilloma (CPP) group pediatric (P). Five CPPs grouped with methylation class CPC (5/17, 29%). In the group of atypical CPPs (n=9), there were two that grouped with methylation class CPC. Survival analysis showed utility of methylation classes in the prediction of biologic behavior. Results indicated that methylation profiling may serve as a valuable tool in the clinical decision-making process for patients with CPTs, providing additional prognostic information compared to WHO histologic grade alone. The value of methylation array analysis is particularly important given the lack of consensus on treatment regimens for CPTs.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
International symposium on inheritable central nervous system (CNS) cancer predisposition: A prologue. Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria. Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort study. Empowering the next generation in neuro-oncology: Introduction of the EANO Career Boost Initiative. A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1